/ Print /

Pharmacy Best Practices

Highly specific indications dominate cancer drug pipelineRecent and pending drug approvals emphasize the growing importance of niche agents for very specific cancer patient populations.
Monetary benefits from value-based diabetes plans take timeValue-based insurance designs for diabetes care improve outcomes, but monetary gains may take years.
FDA challenges abuse-deterrent opioid drug claimThe FDA pushes back on new painkiller’s abuse-deterrent claims. Here’s why this is important to the opioid epidemic.
Study: Patients combine toxic medications with ‘alarming frequency’A new study uses population health analytics to identify potential opioid abuse, and the study findings are troubling.
Three Orphan Drug Program problems and how the FDA plans to fix themRecently, FDA Commissioner Scott Gottlieb announced the FDA will move to close loopholes in the Orphan Drug Program. Here’s what you need to know.
Five ways health executives can impact the opioid crisisConsider these five opportunities to help curb one of the biggest public health issues of the year.
Do antidepressants take more lives than they save?An eye-opening Canadian study has surprising findings about the risk of death and antidepressants.
Pediatric drug market poised for growthMore support for clinical trials and a wider lens for rare diseases in children sets the category on fire.
Beta blockers not needed for heart attack survivors taking these drugsA new study has shocking results about beta blocker use in heart-attack survivors.
Top solutions to lower drug pricesPBMs partnering with pharmacies and drug makers may have a solution to nonadherence due to high pharma costs.